A Canadian cannabis company plans to open a medicinal cannabis manufacturing facility in Launceston after securing an Australian manufacturing licence.
MPX Australia's licence authorises it to cultivate cannabis plants and produce cannabis or cannabis resin for medical purposes at "the company's 70,000 sq. ft. site under construction in Launceston", according to a statement from its parent company MPX International.
Its cannabis products would be destined for the Australian domestic markets.
MPX International chief executive Scott Bowes said in November last year that Tasmania was chosen because of its reputation for producing high quality organic products, the availability of qualified technical staff, and "positive support from local government".
"MPX Australia has commenced the build out of our facility in Launceston which is intended to be in production by mid-2020 subject to final regulatory approvals," he said.
Read more at theadvocate.com.au
